Eurofarma reaffirms its commitment to sustainability by investing in clean sources
Published in: July 29, 2020
and updated in: November 4, 2021
Listen to the text
Stop the audio
Sao Paulo, July 2020 – Eurofarma, a Brazilian pharmaceutical multinational with a presence in 20 Latin American countries, reaffirms its commitment to sustainable development and celebrates the record production of photovoltaic energy at its industrial complex in Itapevi, SP, generating 156,940 kWh, enough to power approximately 900 homes. With an investment of BRL 9.9 million, the company has 7,294 solar panels in operation, with an output of 2.2 GW.
Achieving such energy efficiency goals was only possible by reducing consumption and by the increasingly widespread use of renewable, more environmentally friendly energy sources. The solar panels are installed on the roofs of the Distribution Center, Block 7, Gate, Children’s Space, and the street lighting poles at the Eurofarma Itapevi Complex.
Another important project underway at the company is the update of its entire administrative fleet with hybrid cars. A total of 28 vehicles should be delivered this year, with 150 expected by 2023. Last year, the company invested BRL 13.6 million in sustainable actions and projects.
Less paper
In 2019, in a coordinated effort by the pharmaceutical industry, with the support of Sindusfarma (Pharmaceutical Products Industry Union), a working group was created to speed up the digitization process of new product concession dossiers with Anvisa (Brazilian Health Regulatory Agency). Each new drug registration dossier has from 7,000 to 20,000 pages, including documents, records, and protocols essential for the concession.
With digital uploading becoming a reality, the company trained the corresponding teams to ensure standardization in the specifications of Anvisa’s standards. In addition to the process becoming simpler and faster, Eurofarma saved approximately 80,000 sheets of paper in one year.
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees. www.eurofarma.com.br.
EUROFARMA ON SOCIAL MEDIA
www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarmalab | Twitter: @eurofarmaLab
Achieving such energy efficiency goals was only possible by reducing consumption and by the increasingly widespread use of renewable, more environmentally friendly energy sources. The solar panels are installed on the roofs of the Distribution Center, Block 7, Gate, Children’s Space, and the street lighting poles at the Eurofarma Itapevi Complex.
Another important project underway at the company is the update of its entire administrative fleet with hybrid cars. A total of 28 vehicles should be delivered this year, with 150 expected by 2023. Last year, the company invested BRL 13.6 million in sustainable actions and projects.
Less paper
In 2019, in a coordinated effort by the pharmaceutical industry, with the support of Sindusfarma (Pharmaceutical Products Industry Union), a working group was created to speed up the digitization process of new product concession dossiers with Anvisa (Brazilian Health Regulatory Agency). Each new drug registration dossier has from 7,000 to 20,000 pages, including documents, records, and protocols essential for the concession.
With digital uploading becoming a reality, the company trained the corresponding teams to ensure standardization in the specifications of Anvisa’s standards. In addition to the process becoming simpler and faster, Eurofarma saved approximately 80,000 sheets of paper in one year.
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees. www.eurofarma.com.br.
EUROFARMA ON SOCIAL MEDIA
www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarmalab | Twitter: @eurofarmaLab